1
|
Calado M, Ferreira R, Pires D, Santos-Costa Q, Anes E, Brites D, Azevedo-Pereira JM. Unravelling the triad of neuroinvasion, neurodissemination, and neuroinflammation of human immunodeficiency virus type 1 in the central nervous system. Rev Med Virol 2024; 34:e2534. [PMID: 38588024 DOI: 10.1002/rmv.2534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 03/05/2024] [Accepted: 03/28/2024] [Indexed: 04/10/2024]
Abstract
Since the identification of human immunodeficiency virus type 1 (HIV-1) in 1983, many improvements have been made to control viral replication in the peripheral blood and to treat opportunistic infections. This has increased life expectancy but also the incidence of age-related central nervous system (CNS) disorders and HIV-associated neurodegeneration/neurocognitive impairment and depression collectively referred to as HIV-associated neurocognitive disorders (HAND). HAND encompasses a spectrum of different clinical presentations ranging from milder forms such as asymptomatic neurocognitive impairment or mild neurocognitive disorder to a severe HIV-associated dementia (HAD). Although control of viral replication and suppression of plasma viral load with combination antiretroviral therapy has reduced the incidence of HAD, it has not reversed milder forms of HAND. The objective of this review, is to describe the mechanisms by which HIV-1 invades and disseminates in the CNS, a crucial event leading to HAND. The review will present the evidence that underlies the relationship between HIV infection and HAND. Additionally, recent findings explaining the role of neuroinflammation in the pathogenesis of HAND will be discussed, along with prospects for treatment and control.
Collapse
Affiliation(s)
- Marta Calado
- Host-Pathogen Interactions Unit, Research Institute for Medicines, iMed-ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal
| | - Rita Ferreira
- Host-Pathogen Interactions Unit, Research Institute for Medicines, iMed-ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal
| | - David Pires
- Host-Pathogen Interactions Unit, Research Institute for Medicines, iMed-ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal
- Center for Interdisciplinary Research in Health, Católica Medical School, Universidade Católica Portuguesa, Estrada Octávio Pato, Rio de Mouro, Portugal
| | - Quirina Santos-Costa
- Host-Pathogen Interactions Unit, Research Institute for Medicines, iMed-ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal
| | - Elsa Anes
- Host-Pathogen Interactions Unit, Research Institute for Medicines, iMed-ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal
| | - Dora Brites
- Neuroinflammation, Signaling and Neuroregeneration Unit, Research Institute for Medicines, iMed-ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal
| | - José Miguel Azevedo-Pereira
- Host-Pathogen Interactions Unit, Research Institute for Medicines, iMed-ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal
| |
Collapse
|
2
|
Doganay MT, Roman E, Hujer AM, Bonomo RA, Deeks SG, Kuritzkes DR, Draz MS. AMPLON: Amplifying DNA with Multi-Arm Priming and Looping Optimization of Nucleic Acid. Adv Mater 2024:e2311634. [PMID: 38657970 DOI: 10.1002/adma.202311634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Revised: 04/22/2024] [Indexed: 04/26/2024]
Abstract
Nucleic acid amplification, the bedrock of biotechnology and molecular diagnostics, surges in applications-especially isothermal approaches-heightening the demand for advanced and precisely engineered methods. Here, we present a novel approach for Amplifying DNA with Multi-arm Priming and Looping Optimization of Nucleic Acid (AMPLON). AMPLON relied on a novel polymeric material that utilizes a unique set of multi-arm polyethylene glycol-DNA primers for efficient DNA amplification under isothermal conditions. Each arm carries ssDNA complementing the sense or antisense sequence of the target DNA (n = 6; 50% sense to 50% antisense sequences). The amplification reaction begins with antisense arms binding to the target DNA, forming a template for sense-carrying arms to direct multi-arm large DNA amplicon synthesis through successive DNA looping and unlooping steps. The developed AMPLON enables highly specific and sensitive detection of the targeted nucleic acid sequence. Using HIV-1 as a model clinical target, AMPLON exhibited high sensitivity, detecting target concentrations as low as 100 copies/mL, and selectively amplifying HIV-1 in the presence of other DNA and RNA viruses, such as HBV and HCV. Compared to a quantitative real-time PCR (qRT-PCR) assay using sensitive primers, AMPLON reliably identifies HIV-1 RNA in plasma samples (n = 20) with a significant agreement rate of 95%. With its ability to achieve highly specific and sensitive target amplification within 30 minutes, AMPLON holds immense potential to transform the field of nucleic acid research and unleashing new possibilities in medicine and biotechnology. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Mert Tunca Doganay
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA
| | - Ethan Roman
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA
| | - Andrea M Hujer
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA
- Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA
| | - Robert A Bonomo
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA
- Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA
- Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, OH, USA
| | - Steven G Deeks
- Department of Medicine, University of California, San Francisco, CA, USA
| | - Daniel R Kuritzkes
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, 02115, USA
- Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, 02139, USA
| | - Mohamed S Draz
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA
- Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, OH, USA
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA
- Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH, 44106, USA
| |
Collapse
|
3
|
Ozhmegova E, Lebedev A, Antonova A, Kuznetsova A, Kazennova E, Kim K, Tumanov A, Bobkova M. Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia. HIV Med 2024. [PMID: 38584123 DOI: 10.1111/hiv.13642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Accepted: 03/24/2024] [Indexed: 04/09/2024]
Abstract
BACKGROUND This study aimed to investigate mutations associated with, the causes of, and the conditions that contribute to HIV drug resistance (DR). This research provides crucial insights into the mechanisms through which HIV evades antiretroviral drugs and suggests strategies to counter this phenomenon. Our objective was to assess the prevalence and structure of DR in HIV-1 across various regions in Russia and identify the primary factors influencing the development of HIV DR. METHODS The study used nucleotide sequences from the HIV-1 pol gene obtained from 1369 patients with a history of therapy and virological failure between 2005 and 2019 to analyze the frequency and structure of DR and the factors associated with it. RESULTS The analysed HIV-1 genotypes included viruses resistant to nucleoside reverse transcriptase inhibitors (NRTIs; 11.8%), non-nucleoside reverse transcriptase inhibitors (NNRTIs; 6.4%), and NRTIs + NNRTIs (31.7%). The mutations M184V/I and G190A/S/E were the most prevalent, accounting for 54.5% and 26.6%, respectively. The dominance of multiple DR persisted throughout the entire observation period. The likelihood of encountering drug-resistant variants was increased among men, patients in the late stage of infection, and those with a viral load <30 000 RNA copies/mL. Injection drug use was not associated with DR. CONCLUSION This study has yielded new insights into HIV DR in Russia, offering valuable information to identify clinical or programmatic events warranting closer attention and support.
Collapse
Affiliation(s)
- Ekaterina Ozhmegova
- National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya, Moscow, Russia
| | - Aleksey Lebedev
- National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya, Moscow, Russia
| | - Anastasiia Antonova
- National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya, Moscow, Russia
| | - Anna Kuznetsova
- National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya, Moscow, Russia
| | - Elena Kazennova
- National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya, Moscow, Russia
| | - Kristina Kim
- National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya, Moscow, Russia
| | - Aleksandr Tumanov
- National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya, Moscow, Russia
| | - Marina Bobkova
- I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia
| |
Collapse
|
4
|
Jiang X, Gao Z, Sharma PP, Kumar S, Rathi B, Ji X, Dai J, Xie M, Dong G, Xu S, De Clercq E, Pannecouque C, Dick A, Zhan P, Liu X. Discovery of low-molecular-weight phenylalanine derivatives as novel HIV capsid modulators with improved antiretroviral activity and metabolic stability. J Med Virol 2024; 96:e29594. [PMID: 38576317 DOI: 10.1002/jmv.29594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2023] [Revised: 02/26/2024] [Accepted: 03/26/2024] [Indexed: 04/06/2024]
Abstract
The HIV capsid (CA) protein is a promising target for anti-AIDS treatment due to its critical involvement in viral replication. Herein, we utilized the well-documented CA inhibitor PF74 as our lead compound and designed a series of low-molecular-weight phenylalanine derivatives. Among them, compound 7t exhibited remarkable antiviral activity with a high selection index (EC50 = 0.040 µM, SI = 2815), surpassing that of PF74 (EC50 = 0.50 µM, SI = 258). Furthermore, when evaluated against the HIV-2 strain, 7t (EC50 = 0.13 µM) demonstrated approximately 14-fold higher potency than that of PF74 (EC50 = 1.76 µM). Insights obtained from surface plasmon resonance (SPR) revealed that 7t exhibited stronger target affinity to the CA hexamer and monomer in comparison to PF74. The potential interactions between 7t and the HIV-1 CA were further elucidated using molecular docking and molecular dynamics simulations, providing a plausible explanation for the enhanced target affinity with 7t over PF74. Moreover, the metabolic stability assay demonstrated that 7t (T1/2 = 77.0 min) significantly outperforms PF74 (T1/2 = 0.7 min) in human liver microsome, exhibiting an improvement factor of 110-fold. In conclusion, 7t emerges as a promising drug candidate warranting further investigation.
Collapse
Grants
- National Natural Science Foundation of China (NSFC No. 82173677), Key Research and Development Program, Ministry of Science and Technology of the People's Republic of China (Grant No. 2023YFC2606500; 2023YFE0206500), Science Foundation for Outstanding Young Scholars of Shandong Province (ZR2020JQ31), Shandong Laboratory Program (SYS202205), and NIH/NIAID grant R01AI150491 (Loll, PI, Salvino, Co-I)
- 82173677 National Natural Science Foundation of China
- 2023YFC2606500 Key Research and Development Program, Ministry of Science and Technology of the People's Republic of China
- 2023YFE0206500 Key Research and Development Program, Ministry of Science and Technology of the People's Republic of China
- ZR2020JQ31 Science Foundation for Outstanding Young Scholars of Shandong Province
- SYS202205 Shandong Laboratory Program
- R01AI150491 National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID)
Collapse
Affiliation(s)
- Xiangyi Jiang
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China
| | - Zhen Gao
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China
| | - Prem Prakash Sharma
- HeteroChem InnoTech, Hansraj College Campus (University of Delhi), Delhi, India
| | - Sumit Kumar
- HeteroChem InnoTech, Hansraj College Campus (University of Delhi), Delhi, India
| | - Brijesh Rathi
- H.G. Khorana Centre For Chemical Biology, Department of Chemistry, Hansraj College, University of Delhi, Delhi, India
| | - Xiangkai Ji
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China
| | - Jiaojiao Dai
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China
| | - Minghui Xie
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China
| | - Guanyu Dong
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China
| | - Shujing Xu
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China
| | - Erik De Clercq
- Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Leuven, Belgium
| | - Christophe Pannecouque
- Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Leuven, Belgium
| | - Alexej Dick
- Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
| | - Peng Zhan
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China
- China-Belgium Collaborative Research Center for Innovative Antiviral Drugs of Shandong Province, Jinan, Shandong, People's Republic of China
| | - Xinyong Liu
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China
- China-Belgium Collaborative Research Center for Innovative Antiviral Drugs of Shandong Province, Jinan, Shandong, People's Republic of China
| |
Collapse
|
5
|
Holder KA, Burt K, Grant MD. TIGIT blockade enhances NK cell activity against autologous HIV-1-infected CD4 + T cells. Clin Transl Immunology 2021; 10:e1348. [PMID: 34707863 PMCID: PMC8527024 DOI: 10.1002/cti2.1348] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Revised: 09/21/2021] [Accepted: 09/27/2021] [Indexed: 12/17/2022] Open
Abstract
Objectives During chronic human immunodeficiency virus (HIV)‐1 infection, inhibitory molecules upregulated on lymphocytes contribute to effector cell dysfunction and immune exhaustion. People living with HIV (PLWH) are at greater risk for age‐related morbidities, an issue magnified by human cytomegalovirus (CMV) coinfection. As CMV infection modifies natural killer (NK) cell properties and NK cells contribute to protection against HIV‐1 infection, we considered the role of T‐cell immunoreceptor with immunoglobulin and intracellular tyrosine inhibitory motif domains (TIGIT) in NK cell‐based HIV‐1 immunotherapy and elimination strategies. Methods We measured TIGIT expression on immune cell subsets of 95 PLWH and assessed its impact on NK cell function, including elimination of autologous CD4+ T cells infected through reactivation of endogenous HIV‐1. Results TIGIT was expressed on CD4+ T cells, CD8+ T cells and NK cells from PLWH. Although TIGIT levels on T cells correlated with HIV‐1 disease progression, the extent of TIGIT expression on NK cells more closely paralleled adaptation to CMV. TIGIT interacts with its predominant ligand, poliovirus receptor (PVR), to inhibit effector cell functions. Circulating CD4+ T cells from PLWH more frequently expressed PVR than HIV‐seronegative controls, and PVR expression was enriched in CD4+ T cells replicating HIV‐1 ex vivo. Treatment with anti‐TIGIT monoclonal antibodies increased NK cell HIV‐1‐specific antibody‐dependent cytotoxicity in vitro and ex vivo. Conclusion Blocking TIGIT may be an effective strategy to invigorate antibody‐dependent NK cell activity against HIV‐1 activated in cellular reservoirs for cure or treatment strategies.
Collapse
Affiliation(s)
- Kayla A Holder
- Immunology and Infectious Diseases Program Division of BioMedical Sciences Faculty of Medicine Memorial University of Newfoundland St. John's NL Canada
| | | | - Michael D Grant
- Immunology and Infectious Diseases Program Division of BioMedical Sciences Faculty of Medicine Memorial University of Newfoundland St. John's NL Canada
| |
Collapse
|
6
|
Molla MMA, Yeasmin M, Ghosh AK, Nafisa T, Islam MK, Saif‐Ur‐Rahman K. HIV-1 molecular epidemiology in Bangladesh: A systematic review. Health Sci Rep 2021; 4:e344. [PMID: 34355065 PMCID: PMC8323838 DOI: 10.1002/hsr2.344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Revised: 07/05/2021] [Accepted: 07/19/2021] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND AND AIMS It is postulated that molecular methods along with mathematical modeling can provide critical inference regarding epidemiological parameters, transmission dynamics, spatiotemporal characteristics, and intervention efficacy. Hence, studying molecular epidemiology of human immunodeficiency virus (HIV)-1 infection, especially in resource-limited settings and with a large diaspora of the migrant population such as that of Bangladesh, is of paramount importance. The purpose of this systematic review was to concisely present and discuss the findings from previous studies conducted in Bangladesh regarding HIV-1 subtype prevalence. METHODS Articles were retrieved from six publicly available databases regarding HIV-1 molecular epidemiology using keywords HIV, HIV-1, subtype(s), Bangladesh, and any combination of aforementioned keywords using Boolean operators. A total of 14 articles were downloaded and screened for suitability. Finally, five studies, containing pooled sequences from 317 individuals, were included in this systematic review. RESULTS Results revealed a preponderance of subtype C among HIV-1 infected population (51.10%), followed by circulating recombinant form (CRF)_07BC (15.46%), CRF_01AE (5.68%), A1 (4.73%), CRF_02AG (3.47%), G (3.15%), CRF_62BC (2.84%), B (2.21%), and other subtypes and recombinant forms in small percentages. Subtype C was largely predominant in intravenous drug users as well as female sex workers, whereas the migrant population exhibited a diverse subtype including rare recombinant forms, largely due to their travel in the Middle East and other South East Asian countries. CONCLUSION With the number of HIV-1 infections increasing among the general population and a steady increase in the migrant population, molecular epidemiological data are required to curb the progression of the HIV-1 epidemic in Bangladesh.
Collapse
Affiliation(s)
- Md. Maruf Ahmed Molla
- Department of VirologyNational Institute of Laboratory Medicine and Referral CenterDhakaBangladesh
| | - Mahmuda Yeasmin
- Department of VirologyNational Institute of Laboratory Medicine and Referral CenterDhakaBangladesh
| | | | - Tasnim Nafisa
- Department of VirologyNational Institute of Laboratory Medicine and Referral CenterDhakaBangladesh
| | | | | |
Collapse
|
7
|
Wells L, Vierra C, Hardman J, Han Y, Dimas D, Gwarada-Phillips LN, Blackeye R, Eggers DK, LaBranche CC, Král P, McReynolds KD. Sulfoglycodendrimer Therapeutics for HIV-1 and SARS-CoV-2. Adv Ther (Weinh) 2021; 4:2000210. [PMID: 33786368 PMCID: PMC7995185 DOI: 10.1002/adtp.202000210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Revised: 01/04/2021] [Indexed: 12/05/2022]
Abstract
Hexavalent sulfoglycodendrimers (SGDs) are synthesized as mimics of host cell heparan sulfate proteoglycans (HSPGs) to inhibit the early stages in viral binding/entry of HIV‐1 and SARS‐CoV‐2. Using an HIV neutralization assay, the most promising of the seven candidates are found to have sub‐micromolar anti‐HIV activities. Molecular dynamics simulations are separately implemented to investigate how/where the SGDs interacted with both pathogens. The simulations revealed that the SGDs: 1) develop multivalent binding with polybasic regions within and outside of the V3 loop on glycoprotein 120 (gp120) for HIV‐1, and consecutively bind with multiple gp120 subunits, and 2) interact with basic amino acids in both the angiotensin‐converting enzyme 2 (ACE2) and HSPG binding regions of the Receptor Binding Domain (RBD) from SARS‐CoV‐2. These results illustrate the considerable potential of SGDs as inhibitors in viral binding/entry of both HIV‐1 and SARS‐CoV‐2 pathogens, leading the way for further development of this class of molecules as broad‐spectrum antiviral agents.
Collapse
Affiliation(s)
- Lauren Wells
- Department of Chemistry California State University Sacramento, 6000 J Street Sacramento CA 95819-6057 USA
| | - Cory Vierra
- Department of Chemistry California State University Sacramento, 6000 J Street Sacramento CA 95819-6057 USA
| | - Janee' Hardman
- Department of Chemistry California State University Sacramento, 6000 J Street Sacramento CA 95819-6057 USA
| | - Yanxiao Han
- Department of Chemistry University of Illinois Chicago 845 W. Taylor St. Chicago IL 60607 USA
| | - Dustin Dimas
- Department of Chemistry California State University Sacramento, 6000 J Street Sacramento CA 95819-6057 USA
| | - Lucia N Gwarada-Phillips
- Department of Chemistry California State University Sacramento, 6000 J Street Sacramento CA 95819-6057 USA
| | - Rachel Blackeye
- Department of Chemistry California State University Sacramento, 6000 J Street Sacramento CA 95819-6057 USA
| | - Daryl K Eggers
- Department of Chemistry San José State University One Washington Square San José CA 95192 USA
| | | | - Petr Král
- Department of Chemistry University of Illinois Chicago 845 W. Taylor St. Chicago IL 60607 USA.,Departments of Physics, Pharmaceutical Sciences, and Chemical Engineering University of Illinois Chicago 845 W. Taylor St. Chicago IL 60607 USA
| | - Katherine D McReynolds
- Department of Chemistry California State University Sacramento, 6000 J Street Sacramento CA 95819-6057 USA
| |
Collapse
|
8
|
Nieto‐Garai JA, Arboleya A, Otaegi S, Chojnacki J, Casas J, Fabriàs G, Contreras F, Kräusslich H, Lorizate M. Cholesterol in the Viral Membrane is a Molecular Switch Governing HIV-1 Env Clustering. Adv Sci (Weinh) 2021; 8:2003468. [PMID: 33552873 PMCID: PMC7856888 DOI: 10.1002/advs.202003468] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 10/13/2020] [Indexed: 05/07/2023]
Abstract
HIV-1 entry requires the redistribution of envelope glycoproteins (Env) into a cluster and the presence of cholesterol (chol) in the viral membrane. However, the molecular mechanisms underlying the specific role of chol in infectivity and the driving force behind Env clustering remain unknown. Here, gp41 is demonstrated to directly interact with chol in the viral membrane via residues 751-854 in the cytoplasmic tail (CT751-854). Super-resolution stimulated emission depletion (STED) nanoscopy analysis of Env distribution further demonstrates that both truncation of gp41 CT751-854 and depletion of chol leads to dispersion of Env clusters in the viral membrane and inhibition of virus entry. This work reveals a direct interaction of gp41 CT with chol and indicates that this interaction is an important orchestrator of Env clustering.
Collapse
Affiliation(s)
- Jon Ander Nieto‐Garai
- Instituto Biofisika (UPV/EHU, CSIC)University of the Basque CountryLeioaE‐48940Spain
- Fundación Biofísica Bizkaia/Biofisika Bizkaia Fundazioa (FBB)Barrio Sarriena s/nLeioaE‐48940Spain
| | - Aroa Arboleya
- Instituto Biofisika (UPV/EHU, CSIC)University of the Basque CountryLeioaE‐48940Spain
- Fundación Biofísica Bizkaia/Biofisika Bizkaia Fundazioa (FBB)Barrio Sarriena s/nLeioaE‐48940Spain
| | - Sara Otaegi
- Instituto Biofisika (UPV/EHU, CSIC)University of the Basque CountryLeioaE‐48940Spain
- Department of Biochemistry and Molecular BiologyFaculty of Science and TechnologyUniversity of the Basque CountryLeioaE‐48940Spain
| | | | - Josefina Casas
- Research Unit on BioActive Molecules. Department of Biological ChemistryInstitute for Advanced Chemistry of Catalonia (IQAC‐CSIC)BarcelonaCatalonia08034Spain
- Liver and Digestive Diseases Networking Biomedical Research Center (CIBEREHD) ISCIIMadrid28029Spain
| | - Gemma Fabriàs
- Research Unit on BioActive Molecules. Department of Biological ChemistryInstitute for Advanced Chemistry of Catalonia (IQAC‐CSIC)BarcelonaCatalonia08034Spain
- Liver and Digestive Diseases Networking Biomedical Research Center (CIBEREHD) ISCIIMadrid28029Spain
| | - F‐Xabier Contreras
- Instituto Biofisika (UPV/EHU, CSIC)University of the Basque CountryLeioaE‐48940Spain
- Department of Biochemistry and Molecular BiologyFaculty of Science and TechnologyUniversity of the Basque CountryLeioaE‐48940Spain
- IkerbasqueBasque Foundation for ScienceBilbao48013Spain
| | - Hans‐Georg Kräusslich
- Department of Infectious DiseasesVirologyUniversitätsklinikum HeidelbergHeidelberg69120Germany
| | - Maier Lorizate
- Instituto Biofisika (UPV/EHU, CSIC)University of the Basque CountryLeioaE‐48940Spain
- Department of Biochemistry and Molecular BiologyFaculty of Science and TechnologyUniversity of the Basque CountryLeioaE‐48940Spain
| |
Collapse
|
9
|
Benet S, Gálvez C, Drobniewski F, Kontsevaya I, Arias L, Monguió-Tortajada M, Erkizia I, Urrea V, Ong RY, Luquin M, Dupont M, Chojnacki J, Dalmau J, Cardona P, Neyrolles O, Lugo-Villarino G, Vérollet C, Julián E, Furrer H, Günthard HF, Crocker PR, Tapia G, Borràs FE, Fellay J, McLaren PJ, Telenti A, Cardona PJ, Clotet B, Vilaplana C, Martinez-Picado J, Izquierdo-Useros N. Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles. J Extracell Vesicles 2021; 10:e12046. [PMID: 33489013 PMCID: PMC7807485 DOI: 10.1002/jev2.12046] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Revised: 10/28/2020] [Accepted: 12/01/2020] [Indexed: 12/14/2022] Open
Abstract
The identification of individuals with null alleles enables studying how the loss of gene function affects infection. We previously described a non-functional variant in SIGLEC1, which encodes the myeloid-cell receptor Siglec-1/CD169 implicated in HIV-1 cell-to-cell transmission. Here we report a significant association between the SIGLEC1 null variant and extrapulmonary dissemination of Mycobacterium tuberculosis (Mtb) in two clinical cohorts comprising 6,256 individuals. Local spread of bacteria within the lung is apparent in Mtb-infected Siglec-1 knockout mice which, despite having similar bacterial load, developed more extensive lesions compared to wild type mice. We find that Siglec-1 is necessary to induce antigen presentation through extracellular vesicle uptake. We postulate that lack of Siglec-1 delays the onset of protective immunity against Mtb by limiting antigen exchange via extracellular vesicles, allowing for an early local spread of mycobacteria that increases the risk for extrapulmonary dissemination.
Collapse
Affiliation(s)
- Susana Benet
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain.,Department of Retrovirology Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain
| | - Cristina Gálvez
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain.,Department of Retrovirology Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain
| | | | - Irina Kontsevaya
- Department of Retrovirology Imperial College London UK.,Department of Retrovirology Research Center Borstel, Borstel Germany.,Department of Retrovirology N.V. Postnikov Samara Region Clinical Tuberculosis Dispensary Samara Russia
| | - Lilibeth Arias
- Experimental Tuberculosis Unit (UTE) Germans Trias i Pujol Health Science Research Institute Can Ruti Campus Badalona Spain.,Departament de Genètica i de Microbiologia Facultat de Biociències Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain.,Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) Madrid Spain
| | - Marta Monguió-Tortajada
- REMAR-IVECAT Group Germans Trias i Pujol Health Science Research Institute Can Ruti Campus Badalona Spain.,ICREC Research Program Germans Trias i Pujol Health Science Research Institute Can Ruti Campus Badalona Spain.,Department of Cell Biology Physiology and Immunology Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain
| | - Itziar Erkizia
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain
| | - Victor Urrea
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain
| | - Ruo-Yan Ong
- Division of Cell Signalling and Immunology University of Dundee Dundee UK
| | - Marina Luquin
- Departament de Genètica i de Microbiologia Facultat de Biociències Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain
| | - Maeva Dupont
- Institut de Pharmacologie et Biologie Structurale IPBS CNRS UPS Université de Toulouse Toulouse France.,International associated laboratory (LIA) CNRS "IM-TB/HIV" (1167) France and Buenos Aires Toulouse Argentina
| | - Jakub Chojnacki
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain
| | - Judith Dalmau
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain
| | - Paula Cardona
- Experimental Tuberculosis Unit (UTE) Germans Trias i Pujol Health Science Research Institute Can Ruti Campus Badalona Spain.,Departament de Genètica i de Microbiologia Facultat de Biociències Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain.,Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) Madrid Spain
| | - Olivier Neyrolles
- Institut de Pharmacologie et Biologie Structurale IPBS CNRS UPS Université de Toulouse Toulouse France.,International associated laboratory (LIA) CNRS "IM-TB/HIV" (1167) France and Buenos Aires Toulouse Argentina
| | - Geanncarlo Lugo-Villarino
- Institut de Pharmacologie et Biologie Structurale IPBS CNRS UPS Université de Toulouse Toulouse France.,International associated laboratory (LIA) CNRS "IM-TB/HIV" (1167) France and Buenos Aires Toulouse Argentina
| | - Christel Vérollet
- Institut de Pharmacologie et Biologie Structurale IPBS CNRS UPS Université de Toulouse Toulouse France.,International associated laboratory (LIA) CNRS "IM-TB/HIV" (1167) France and Buenos Aires Toulouse Argentina
| | - Esther Julián
- Departament de Genètica i de Microbiologia Facultat de Biociències Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain
| | - Hansjakob Furrer
- Department of Infectious Diseases Bern University Hospital University of Bern Bern Switzerland
| | - Huldrych F Günthard
- Division of Infectious Diseases and Hospital Epidemiology University Hospital Zurich Zurich Switzerland.,Institute of Medical Virology University of Zurich Zurich Switzerland
| | - Paul R Crocker
- Division of Cell Signalling and Immunology University of Dundee Dundee UK
| | - Gustavo Tapia
- Department of Retrovirology Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain.,Pathology Department Hospital Universitario Germans Trias i Pujol Badalona Spain.,Germans Trias i Pujol Research Institute (IGTP) Can Ruti Campus Badalona Spain
| | - Francesc E Borràs
- REMAR-IVECAT Group Germans Trias i Pujol Health Science Research Institute Can Ruti Campus Badalona Spain.,Nephrology Department Germans Trias i Pujol University Hospital Badalona Spain
| | - Jacques Fellay
- School of Life Sciences École Polytechnique Fédérale de Lausanne Lausanne Switzerland.,Swiss Institute of Bioinformatics Lausanne Switzerland.,Precision Medicine Unit Lausanne University Hospital and University of Lausanne Lausanne Switzerland
| | - Paul J McLaren
- JC Wilt Infectious Diseases Research Centre Public Health Agency of Canada Winnipeg Manitoba Canada.,Department of Medical Microbiology and Infectious Diseases University of Manitoba Winnipeg Manitoba Canada
| | | | - Pere-Joan Cardona
- Experimental Tuberculosis Unit (UTE) Germans Trias i Pujol Health Science Research Institute Can Ruti Campus Badalona Spain.,Departament de Genètica i de Microbiologia Facultat de Biociències Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain.,Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) Madrid Spain
| | - Bonaventura Clotet
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain.,Germans Trias i Pujol Research Institute (IGTP) Can Ruti Campus Badalona Spain.,AIDS and Related Illnesses Centre for Health and Social Care Research (CESS) Faculty of Medicine University of Vic - Central University of Catalonia (UVic - UCC) Vic Spain
| | - Cristina Vilaplana
- Experimental Tuberculosis Unit (UTE) Germans Trias i Pujol Health Science Research Institute Can Ruti Campus Badalona Spain.,Departament de Genètica i de Microbiologia Facultat de Biociències Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain.,Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) Madrid Spain
| | - Javier Martinez-Picado
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain.,Germans Trias i Pujol Research Institute (IGTP) Can Ruti Campus Badalona Spain.,AIDS and Related Illnesses Centre for Health and Social Care Research (CESS) Faculty of Medicine University of Vic - Central University of Catalonia (UVic - UCC) Vic Spain.,Catalan Institution for Research and Advanced Studies (ICREA) Barcelona Spain
| | - Nuria Izquierdo-Useros
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain.,Germans Trias i Pujol Research Institute (IGTP) Can Ruti Campus Badalona Spain
| |
Collapse
|
10
|
Zhao Z, Muth DC, Mulka K, Liao Z, Powell BH, Hancock GV, Metcalf Pate KA, Witwer KW. miRNA profiling of primate cervicovaginal lavage and extracellular vesicles reveals miR-186-5p as a potential antiretroviral factor in macrophages. FEBS Open Bio 2020; 10:2021-2039. [PMID: 33017084 PMCID: PMC7530394 DOI: 10.1002/2211-5463.12952] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Revised: 06/03/2020] [Accepted: 08/13/2020] [Indexed: 12/15/2022] Open
Abstract
Cervicovaginal secretions, or their components collected, are referred to as cervicovaginal lavage (CVL). CVL constituents have utility as biomarkers and play protective roles in wound healing and against HIV-1 infection. However, several components of cervicovaginal fluids are less well understood, such as extracellular RNAs and their carriers, for example, extracellular vesicles (EVs). EVs comprise a wide array of double-leaflet membrane extracellular particles and range in diameter from 30 nm to over one micron. The aim of this study was to determine whether differentially regulated CVL microRNAs (miRNAs) might influence retrovirus replication. To this end, we characterized EVs and miRNAs of primate CVL during the menstrual cycle and simian immunodeficiency virus (SIV) infection of macaques. EVs were enriched by stepped ultracentrifugation, and miRNA profiles were assessed with a medium-throughput stem-loop/hydrolysis probe qPCR platform. Whereas hormone cycling was abnormal in infected subjects, EV concentration correlated with progesterone concentration in uninfected subjects. miRNAs were present predominantly in the EV-depleted CVL supernatant. Only a small number of CVL miRNAs changed during the menstrual cycle or SIV infection, for example, miR-186-5p, which was depleted in retroviral infection. This miRNA inhibited HIV replication in infected macrophages in vitro. In silico target prediction and pathway enrichment analyses shed light on the probable functions of miR-186-5p in hindering HIV infections via immunoregulation, T-cell regulation, disruption of viral pathways, etc. These results provide further evidence for the potential of EVs and small RNAs as biomarkers or effectors of disease processes in the reproductive tract.
Collapse
Affiliation(s)
- Zezhou Zhao
- Department of Molecular and Comparative PathobiologyThe Johns Hopkins University School of MedicineBaltimoreMDUSA
| | - Dillon C. Muth
- Department of Molecular and Comparative PathobiologyThe Johns Hopkins University School of MedicineBaltimoreMDUSA
| | - Kathleen Mulka
- Department of Molecular and Comparative PathobiologyThe Johns Hopkins University School of MedicineBaltimoreMDUSA
| | - Zhaohao Liao
- Department of Molecular and Comparative PathobiologyThe Johns Hopkins University School of MedicineBaltimoreMDUSA
| | - Bonita H. Powell
- Department of Molecular and Comparative PathobiologyThe Johns Hopkins University School of MedicineBaltimoreMDUSA
| | | | - Kelly A. Metcalf Pate
- Department of Molecular and Comparative PathobiologyThe Johns Hopkins University School of MedicineBaltimoreMDUSA
| | - Kenneth W. Witwer
- Department of Molecular and Comparative PathobiologyThe Johns Hopkins University School of MedicineBaltimoreMDUSA
- Department of NeurologyThe Johns Hopkins University School of MedicineBaltimoreMDUSA
| |
Collapse
|
11
|
Hijmans JG, Stockelman KA, Garcia V, Levy MV, Brewster LM, Bammert TD, Greiner JJ, Stauffer BL, Connick E, DeSouza CA. Circulating Microparticles Are Elevated in Treated HIV -1 Infection and Are Deleterious to Endothelial Cell Function. J Am Heart Assoc 2020; 8:e011134. [PMID: 30779672 PMCID: PMC6405669 DOI: 10.1161/jaha.118.011134] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Background Circulating microparticles have emerged as biomarkers and effectors of vascular disease. Elevated rates of cardiovascular disease are seen in HIV -1-seropositive individuals. The aims of this study were to determine: (1) if circulating microparticles are elevated in antiretroviral therapy-treated HIV -1-seropositive adults; and (2) the effects of microparticles isolated from antiretroviral therapy -treated HIV -1-seropositive adults on endothelial cell function, in vitro. Methods and Results Circulating levels of endothelial-, platelet-, monocyte-, and leukocyte-derived microparticles were determined by flow cytometry in plasma from 15 healthy and 15 antiretroviral therapy-treated, virologically suppressed HIV -1-seropositive men. Human umbilical vein endothelial cells were treated with microparticles from individual subjects for 24 hours; thereafter, endothelial cell inflammation, oxidative stress, senescence, and apoptosis were assessed. Circulating concentrations of endothelial-, platelet-, monocyte-, and leukocyte-derived microparticles were significantly higher (≈35%-225%) in the HIV -1-seropositive compared with healthy men. Microparticles from HIV -1-seropositive men induced significantly greater endothelial cell release of interleukin-6 and interleukin-8 (≈20% and ≈35%, respectively) and nuclear factor-κB expression while suppressing anti-inflammatory microRNAs (miR-146a and miR-181b). Intracellular reactive oxygen species production and expression of reactive oxygen species -related heat shock protein 70 were both higher in cells treated with microparticles from the HIV -1-seropositive men. In addition, the percentage of senescent cells was significantly higher and sirtuin 1 expression lower in cells treated with HIV -1-related microparticles. Finally, caspase-3 was significantly elevated by microparticles from HIV -1-seropositive men. Conclusions Circulating concentrations of endothelial-, platelet-, monocyte-, and leukocyte-derived microparticles were higher in antiretroviral therapy-treated HIV -1-seropositive men and adversely affect endothelial cells promoting cellular inflammation, oxidative stress, senescence, and apoptosis. Circulating microparticles may contribute to the vascular risk associated with HIV -1 infection.
Collapse
Affiliation(s)
- Jamie G Hijmans
- 1 Integrative Vascular Biology Laboratory Department of Integrative Physiology University of Colorado Boulder Boulder CO
| | - Kelly A Stockelman
- 1 Integrative Vascular Biology Laboratory Department of Integrative Physiology University of Colorado Boulder Boulder CO
| | - Vinicius Garcia
- 1 Integrative Vascular Biology Laboratory Department of Integrative Physiology University of Colorado Boulder Boulder CO
| | - Ma'ayan V Levy
- 1 Integrative Vascular Biology Laboratory Department of Integrative Physiology University of Colorado Boulder Boulder CO
| | - L Madden Brewster
- 1 Integrative Vascular Biology Laboratory Department of Integrative Physiology University of Colorado Boulder Boulder CO
| | - Tyler D Bammert
- 1 Integrative Vascular Biology Laboratory Department of Integrative Physiology University of Colorado Boulder Boulder CO
| | - Jared J Greiner
- 1 Integrative Vascular Biology Laboratory Department of Integrative Physiology University of Colorado Boulder Boulder CO
| | - Brian L Stauffer
- 2 Department of Medicine Anschutz Medical Center University of Colorado Denver Denver CO.,3 Denver Health Medical Center Denver CO
| | | | - Christopher A DeSouza
- 1 Integrative Vascular Biology Laboratory Department of Integrative Physiology University of Colorado Boulder Boulder CO.,2 Department of Medicine Anschutz Medical Center University of Colorado Denver Denver CO
| |
Collapse
|
12
|
Hashemi P, Barreto K, Bernhard W, Lomness A, Honson N, Pfeifer TA, Harrigan PR, Sadowski I. Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency. EMBO Mol Med 2019; 10:160-174. [PMID: 29246970 PMCID: PMC5838563 DOI: 10.15252/emmm.201708193] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Highly active antiretroviral therapy (HAART) has improved the outlook for the HIV epidemic, but does not provide a cure. The proposed “shock‐and‐kill” strategy is directed at inducing latent HIV reservoirs, which may then be purged via boosted immune response or targeting infected cells. We describe five novel compounds that are capable of reversing HIV latency without affecting the general T‐cell activation state. The new compounds exhibit synergy for reactivation of latent provirus with other latency‐reversing agents (LRAs), in particular ingenol‐3‐angelate/PEP005. One compound, designated PH02, was efficient at reactivating viral transcription in several cell lines bearing reporter HIV‐1 at different integration sites. Furthermore, it was capable of reversing latency in resting CD4+ T lymphocytes from latently infected aviremic patient cells on HAART, while producing minimal cellular toxicity. The combination of PH02 and PEP005 produces a strong synergistic effect for reactivation, as demonstrated through a quantitative viral outgrowth assay (qVOA), on CD4+ T lymphocytes from HIV‐1‐infected individuals. We propose that the PH02/PEP005 combination may represent an effective novel treatment for abrogating persistent HIV‐1 infection.
Collapse
Affiliation(s)
- Pargol Hashemi
- Biochemistry and Molecular Biology, Molecular Epigenetics, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada
| | - Kris Barreto
- Biochemistry and Molecular Biology, Molecular Epigenetics, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada
| | - Wendy Bernhard
- Biochemistry and Molecular Biology, Molecular Epigenetics, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada
| | - Adam Lomness
- Biochemistry and Molecular Biology, Molecular Epigenetics, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada
| | - Nicolette Honson
- The Centre for Drug Research and Development, Vancouver, BC, Canada
| | - Tom A Pfeifer
- The Centre for Drug Research and Development, Vancouver, BC, Canada
| | - P Richard Harrigan
- BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada
| | - Ivan Sadowski
- Biochemistry and Molecular Biology, Molecular Epigenetics, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada
| |
Collapse
|
13
|
Nakanishi S, Watanabe S, Doi N, Koma T, Adachi A, Nomaguchi M. Virological characterization of HIV-1 CA-NTD mutants constructed in a virus-lineage reflected manner. J Med Invest 2018; 65:110-115. [PMID: 29593179 DOI: 10.2152/jmi.65.110] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Capsid (CA) protein is a major virion-constituent of all retroviruses including human immunodeficiency virus type 1 (HIV-1), and is essential for early and late phases in viral replication cycle through interaction with numerous cellular factors. In particular, N-terminal domain (NTD) of HIV-1 CA has been frequently and well reported to bind to various host cell proteins that considerably affect viral replication potential. In this study, in order to better define biological bases of the CA-NTD for HIV-1 replication, we performed an extensive mutational analysis in an unprecedented manner. By aligning CA-NTD sequences derived from representative infectious molecular clones of HIV-1, HIV-2, and simian immunodeficiency virus isolated from the rhesus macaque (SIVmac), a number of amino acids specific to HIV-1 were selected, and were replaced with those from SIVmac at the corresponding sites. Mutant viruses thus generated were then examined for multi-cycle infectivity, single-cycle infectivity, and ability to produce progeny virions. While some CA-NTD mutations affected viral replication ability to varying degrees, those in helix 7 abolished viral growth potential without exception. These results highlight functional importance of non-conserved amino acids in helix 7, and give new insights into functionality of HIV-1 CA-NTD. J. Med. Invest. 65:110-115, February, 2018.
Collapse
Affiliation(s)
- Shoko Nakanishi
- Department of Microbiology, Tokushima University Graduate School of Medical Science
| | - Sakimi Watanabe
- Department of Microbiology, Tokushima University Graduate School of Medical Science
| | - Naoya Doi
- Department of Microbiology, Tokushima University Graduate School of Medical Science
| | - Takaaki Koma
- Department of Microbiology, Tokushima University Graduate School of Medical Science
| | - Akio Adachi
- Department of Microbiology, Kansai Medical University
| | - Masako Nomaguchi
- Department of Microbiology, Tokushima University Graduate School of Medical Science
| |
Collapse
|
14
|
Longo S, Bon I, Musumeci G, Bertoldi A, D'Urbano V, Calza L, Re MC. Comparison of the Aptima HIV-1 Quant Dx assay with the COBAS AmpliPrep/COBAS TaqMan HIV-1 v2.0 Test for HIV-1 viral load quantification in plasma samples from HIV-1-infected patients. Health Sci Rep 2018; 1:e31. [PMID: 30623066 PMCID: PMC6266574 DOI: 10.1002/hsr2.31] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 02/03/2018] [Accepted: 02/07/2018] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND AND AIMS HIV-1 RNA viral load (VL) in plasma samples of HIV-1-positive patients is used to assess the level of viral replication, the risk of disease progression, and the response and efficacy to antiretroviral treatment. Knowing the performance of different tests for HIV-1 RNA detection is, therefore, important for clinical care. This study compared the performance of the recently introduced Aptima HIV-1 Quant Dx assay (Hologic, Inc) and the standard COBAS AmpliPrep/COBAS TaqMan HIV-1 v2.0 Test (CAP/CTM2) (Roche Molecular System, Inc) for HIV-1 RNA quantitation. METHODS Assay performance was assessed using 335 clinical samples, a standard HIV-1 low VL panel, and 2 diluted samples from well-characterized patients infected with different HIV-1 subtypes tested in 5 replicates over 3 days. All samples were tested on both assays to evaluate inter-assay agreement, both qualitatively and quantitively. Altogether, we evaluated assay sensitivity, linearity, accuracy, precision, repeatability, and reproducibility. RESULTS Assay agreement for qualitative results in 335 clinical samples was fair (80.6%). Correlation of quantitative assay results (n = 164) was excellent (R 2 = 0.97), with 96.3% of the results within the 95% limit of assay agreement (-0.42 to +0.86 log), and 98.8% within 1 log of each other. Aptima-HIV-1 yielded results, on average, 0.22 log higher than CAP/CTM2. Both assays accurately quantitated the HIV-1 standard at low VL (R 2 ≥ 0.94), with all samples within 0.5 log of the target. CONCLUSION Aptima-HIV-1 assay demonstrated sensitivity, accuracy, reproducibility, and precision for the detection and quantitation of HIV-1 RNA across a wide dynamic range of VLs. Its performance, together with full automation and high throughput, suggests that Aptima-HIV-1 could be a suitable assay for reliable monitoring of HIV-1 VL in patients undergoing treatment.
Collapse
Affiliation(s)
- Serena Longo
- Microbiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of MedicineUniversity of BolognaItaly
| | - Isabella Bon
- Microbiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of MedicineUniversity of BolognaItaly
| | - Giuseppina Musumeci
- Microbiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of MedicineUniversity of BolognaItaly
| | - Alessia Bertoldi
- Microbiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of MedicineUniversity of BolognaItaly
| | - Vanessa D'Urbano
- Microbiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of MedicineUniversity of BolognaItaly
| | - Leonardo Calza
- Clinics of Infectious Diseases, Department of Medical and Surgical SciencesSt. Orsola‐Malpighi Hospital, University of BolognaItaly
| | - Maria Carla Re
- Microbiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of MedicineUniversity of BolognaItaly
| |
Collapse
|
15
|
Takagi S, Momose F, Morikawa Y. FRET analysis of HIV-1 Gag and GagPol interactions. FEBS Open Bio 2017; 7:1815-1825. [PMID: 29123989 PMCID: PMC5666392 DOI: 10.1002/2211-5463.12328] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2017] [Revised: 09/26/2017] [Accepted: 09/26/2017] [Indexed: 11/26/2022] Open
Abstract
The Gag protein of HIV multimerizes to form viral particles. The GagPol protein encoding virus‐specific enzymes, such as protease, reverse transcriptase, and integrase, is incorporated into HIV particles via interactions with Gag. The catalytically active forms of these enzymes are dimeric or tetrameric. We employed Förster resonance energy transfer (FRET) assays to evaluate Gag–Gag, Gag–GagPol, and GagPol–GagPol interactions and investigated Gag and Pol interdomains tolerant to fluorescent protein insertion for FRET assays. Our data indicated that the matrix (MA)–capsid (CA) domain junction in the Gag region and the Gag C terminus were equally available for Gag–Gag and Gag–GagPol interaction assays. For GagPol dimerization assays, insertion at the MA–CA domain junction was most favorable.
Collapse
Affiliation(s)
- Shimon Takagi
- Kitasato Institute for Life Sciences and Graduate School for Infection Control Kitasato University Tokyo Japan.,Present address: A2 Healthcare Corporation Sumitomo Fudosan Korakuen Bldg., Koishikawa 1-4-1, Bunkyo-ku Tokyo 112-0002 Japan
| | - Fumitaka Momose
- Kitasato Institute for Life Sciences and Graduate School for Infection Control Kitasato University Tokyo Japan
| | - Yuko Morikawa
- Kitasato Institute for Life Sciences and Graduate School for Infection Control Kitasato University Tokyo Japan
| |
Collapse
|
16
|
Amaral AJ, Andrade J, Foxall RB, Matoso P, Matos AM, Soares RS, Rocha C, Ramos CG, Tendeiro R, Serra-Caetano A, Guerra-Assunção JA, Santa-Marta M, Gonçalves J, Gama-Carvalho M, Sousa AE. miRNA profiling of human naive CD4 T cells links miR-34c-5p to cell activation and HIV replication. EMBO J 2017; 36:346-360. [PMID: 27993935 PMCID: PMC5286376 DOI: 10.15252/embj.201694335] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2016] [Revised: 10/25/2016] [Accepted: 10/31/2016] [Indexed: 01/16/2023] Open
Abstract
Cell activation is a vital step for T-cell memory/effector differentiation as well as for productive HIV infection. To identify novel regulators of this process, we used next-generation sequencing to profile changes in microRNA expression occurring in purified human naive CD4 T cells in response to TCR stimulation and/or HIV infection. Our results demonstrate, for the first time, the transcriptional up-regulation of miR-34c-5p in response to TCR stimulation in naive CD4 T cells. The induction of this miR was further consistently found to be reduced by both HIV-1 and HIV-2 infections. Overexpression of miR-34c-5p led to changes in the expression of several genes involved in TCR signaling and cell activation, confirming its role as a novel regulator of naive CD4 T-cell activation. We additionally show that miR-34c-5p promotes HIV-1 replication, suggesting that its down-regulation during HIV infection may be part of an anti-viral host response.
Collapse
Affiliation(s)
- Andreia J Amaral
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
- University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Lisboa, Portugal
| | - Jorge Andrade
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
- University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Lisboa, Portugal
| | - Russell B Foxall
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - Paula Matoso
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - Ana M Matos
- University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Lisboa, Portugal
| | - Rui S Soares
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - Cheila Rocha
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - Christian G Ramos
- University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Lisboa, Portugal
| | - Rita Tendeiro
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - Ana Serra-Caetano
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - José A Guerra-Assunção
- Bill Lyons Informatics Centre, UCL Cancer Institute, University College London, London, UK
| | - Mariana Santa-Marta
- Research Institute for Medicines (iMed ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal
| | - João Gonçalves
- Research Institute for Medicines (iMed ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal
| | - Margarida Gama-Carvalho
- University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Lisboa, Portugal
| | - Ana E Sousa
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| |
Collapse
|
17
|
Inoue M, Oyama D, Hidaka K, Kameoka M. Evaluation of novel protease inhibitors against darunavir-resistant variants of HIV type 1. FEBS Open Bio 2017; 7:88-95. [PMID: 28097091 PMCID: PMC5221448 DOI: 10.1002/2211-5463.12160] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 11/02/2016] [Accepted: 11/05/2016] [Indexed: 02/06/2023] Open
Abstract
HIV disease became a manageable chronic disease since combination antiretroviral therapy (cART) was introduced as the standard treatment regimen. However, the emergence of drug‐resistant viruses is a major problem associated with cART. A phenotypic drug susceptibility test using a lentiviral vector was established and applied to evaluate new protease inhibitors (PIs). Lentiviral vectors representing a wild‐type (WT‐lentivector) and darunavir (DRV)‐resistant HIV type 1 (HIV‐1) (DRVr‐lentivector) were generated. Nine clinically approved protease inhibitors (PIs) inhibited the transduction ability of WT‐lentivector similar to their inhibitory effects on the replication of WT HIV‐1. Three new PIs reduced the transduction ability of WT‐ and DRVr‐lentivector, suggesting that these PIs may be the candidates as novel antiretroviral drugs against drug‐resistant variants of HIV‐1.
Collapse
Affiliation(s)
- Mari Inoue
- Department of International Health Kobe University Graduate School of Health Sciences Hyogo Japan
| | - Daiki Oyama
- Department of International Health Kobe University Graduate School of Health Sciences Hyogo Japan
| | - Koushi Hidaka
- Faculty of Pharmaceutical Sciences Kobe Gakuin University Hyogo Japan
| | - Masanori Kameoka
- Department of International Health Kobe University Graduate School of Health Sciences Hyogo Japan
| |
Collapse
|
18
|
Berg C, Spiess K, Lüttichau HR, Rosenkilde MM. Biased small-molecule ligands for selective inhibition of HIV-1 cell entry via CCR5. Pharmacol Res Perspect 2016; 4:e00262. [PMID: 28097000 PMCID: PMC5226280 DOI: 10.1002/prp2.262] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Accepted: 08/16/2016] [Indexed: 12/31/2022] Open
Abstract
Since the discovery of HIV's use of CCR5 as the primary coreceptor in fusion, the focus on developing small-molecule receptor antagonists for inhibition hereof has only resulted in one single drug, Maraviroc. We therefore investigated the possibility of using small-molecule CCR5 agonists as HIV-1 fusion inhibitors. A virus-free cell-based fusion reporter assay, based on mixing "effector cells" (expressing HIV Env and luciferase activator) with "target cells" (expressing CD4, CCR5 wild type or a selection of well-described mutations, and luciferase reporter), was used as fusion readout. Receptor expression was evaluated by ELISA and fluorescence microscopy. On CCR5 WT, Maraviroc and Aplaviroc inhibited fusion with high potencies (EC 50 values of 91 and 501 nM, respectively), whereas removal of key residues for both antagonists (Glu283Ala) or Maraviroc alone (Tyr251Ala) prevented fusion inhibition, establishing this assay as suitable for screening of HIV entry inhibitors. Both ligands inhibited HIV fusion on signaling-deficient CCR5 mutations (Tyr244Ala and Trp248Ala). Moreover, the steric hindrance CCR5 mutation (Gly286Phe) impaired fusion, presumably by a direct hindrance of gp120 interaction. Finally, the efficacy switch mutation (Leu203Phe) - converting small-molecule antagonists/inverse agonists to full agonists biased toward G-protein activation - uncovered that also small-molecule agonists can function as direct HIV-1 cell entry inhibitors. Importantly, no agonist-induced receptor internalization was observed for this mutation. Our studies of the pharmacodynamic requirements for HIV-1 fusion inhibitors highlight the possibility of future development of biased ligands with selective targeting of the HIV-CCR5 interaction without interfering with the normal functionality of CCR5.
Collapse
Affiliation(s)
- Christian Berg
- Department of Neuroscience and PharmacologyFaculty of Health and Medical SciencesThe Panum InstituteUniversity of CopenhagenCopenhagenDenmark
| | - Katja Spiess
- Department of Neuroscience and PharmacologyFaculty of Health and Medical SciencesThe Panum InstituteUniversity of CopenhagenCopenhagenDenmark
| | - Hans R. Lüttichau
- Department of Neuroscience and PharmacologyFaculty of Health and Medical SciencesThe Panum InstituteUniversity of CopenhagenCopenhagenDenmark
- Department of MedicineInfectious Disease UnitHerlev HospitalCopenhagenDenmark
| | - Mette M. Rosenkilde
- Department of Neuroscience and PharmacologyFaculty of Health and Medical SciencesThe Panum InstituteUniversity of CopenhagenCopenhagenDenmark
| |
Collapse
|
19
|
Tóth F, Kádas J, Mótyán JA, Tőzsér J. Effect of internal cleavage site mutations in human immunodeficiency virus type 1 capsid protein on its structure and function. FEBS Open Bio 2016; 6:847-59. [PMID: 27516963 PMCID: PMC4971840 DOI: 10.1002/2211-5463.12094] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2016] [Revised: 05/12/2016] [Accepted: 05/26/2016] [Indexed: 12/13/2022] Open
Abstract
The capsid protein of the human immunodeficiency virus type 1 has been found to be a substrate of the retroviral protease in vitro, and its processing was predicted to be strongly dependent on a pH‐induced conformational change. Several protease cleavage sites have been identified within the capsid protein, but the importance of its cleavage by the viral protease at the early phase of infection is controversial. To confirm the relevance of this process, we aimed to design, produce, and characterize mutant capsid proteins, in which the protein susceptibility toward HIV‐1 protease is altered without affecting other steps of the viral life cycle. Our results indicate that while the introduced mutations changed the cleavage rate at the mutated sites of the capsid protein by HIV‐1 protease, some of them caused only negligible or moderate structural changes (A78V, L189F, and L189I). However, the effects of other mutations (W23A, A77P, and L189P) were dramatic, as assessed by secondary structure determination or cyclophilin A‐binding assay. Based on our observations, the L189F mutant capsid remains structurally and functionally unchanged and may therefore be the best candidate for use in studies aimed at better understanding the role of the protease in the early postentry events of viral infection or retrovirus‐mediated gene transduction.
Collapse
Affiliation(s)
- Ferenc Tóth
- Department of Biochemistry and Molecular Biology Faculty of Medicine University of Debrecen Hungary
| | - János Kádas
- Department of Biochemistry and Molecular Biology Faculty of Medicine University of Debrecen Hungary
| | - János András Mótyán
- Department of Biochemistry and Molecular Biology Faculty of Medicine University of Debrecen Hungary
| | - József Tőzsér
- Department of Biochemistry and Molecular Biology Faculty of Medicine University of Debrecen Hungary
| |
Collapse
|
20
|
Ammar FF, Hobaika Z, Abdel-Azeim S, Zargarian L, Maroun RG, Fermandjian S. A targeted DNA substrate mechanism for the inhibition of HIV-1 integrase by inhibitors with antiretroviral activity. FEBS Open Bio 2016; 6:234-50. [PMID: 27239438 PMCID: PMC4821353 DOI: 10.1002/2211-5463.12025] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Revised: 11/25/2015] [Accepted: 12/16/2015] [Indexed: 12/21/2022] Open
Abstract
We recently reported that viral DNA could be the primary target of raltegravir (RAL), an efficient anti‐HIV‐1 drug, which acts by inhibiting integrase. To elucidate this mechanism, we conducted a comparative analysis of RAL and TB11, a diketoacid abandoned as an anti‐HIV‐1 drug for its weak efficiency and marked toxicity, and tested the effects of the catalytic cofactor Mg2+ (5 mm) on drug‐binding properties. We used circular dichroism and fluorescence to determine drug affinities for viral DNA long terminal repeats (LTRs) and peptides derived from the integrase active site and DNA retardation assays to assess drug intercalation into DNA base pairs. We found that RAL bound more tightly to LTR ends than did TB11 (a diketo acid bearing an azido group) and that Mg2+ significantly increased the affinity of both RAL and TB11. We also observed a good relationship between drug binding with processed LTR and strand transfer inhibition. This unusual type of inhibition was caused by Mg2+‐assisted binding of drugs to DNA substrate, rather than to enzyme. Notably, while RAL bound exclusively to the cleavable/cleaved site, TB11 further intercalated into DNA base pairs and interacted with the integrase‐derived peptides. These unwanted binding sites explain the weaker bioavailability and higher toxicity of TB11 compared with the more effective RAL.
Collapse
Affiliation(s)
- Farah F Ammar
- Centre d'Analyses et de Recherche UR EGFEM Faculté des Sciences Université Saint-Joseph Beirut Lebanon; LBPA, UMR8113 du CNRS Ecole Normale Supérieure de Cachan Cedex Cachan France
| | - Zeina Hobaika
- Centre d'Analyses et de Recherche UR EGFEM Faculté des Sciences Université Saint-Joseph Beirut Lebanon
| | - Safwat Abdel-Azeim
- LBPA, UMR8113 du CNRS Ecole Normale Supérieure de Cachan Cedex Cachan France
| | - Loussinée Zargarian
- LBPA, UMR8113 du CNRS Ecole Normale Supérieure de Cachan Cedex Cachan France
| | - Richard G Maroun
- Centre d'Analyses et de Recherche UR EGFEM Faculté des Sciences Université Saint-Joseph Beirut Lebanon
| | - Serge Fermandjian
- LBPA, UMR8113 du CNRS Ecole Normale Supérieure de Cachan Cedex Cachan France; Chemistry and Biology, Nucleo(s)tides and Immunology for Therapy UMR8601 CNRS Paris Cedex 06 France
| |
Collapse
|
21
|
Mahauad-Fernandez WD, Okeoma CM. The role of BST-2/Tetherin in host protection and disease manifestation. Immun Inflamm Dis 2015; 4:4-23. [PMID: 27042298 PMCID: PMC4768070 DOI: 10.1002/iid3.92] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Revised: 11/07/2015] [Accepted: 11/09/2015] [Indexed: 12/21/2022]
Abstract
Host cells respond to viral infections by activating immune response genes that are not only involved in inflammation, but may also predispose cells to cancerous transformation. One such gene is BST‐2, a type II transmembrane protein with a unique topology that endows it tethering and signaling potential. Through this ability to tether and signal, BST‐2 regulates host response to viral infection either by inhibiting release of nascent viral particles or in some models inhibiting viral dissemination. However, despite its antiviral functions, BST‐2 is involved in disease manifestation, a function linked to the ability of BST‐2 to promote cell‐to‐cell interaction. Therefore, modulating BST‐2 expression and/or activity has the potential to influence course of disease.
Collapse
Affiliation(s)
- Wadie D Mahauad-Fernandez
- Department of MicrobiologyCarver College of MedicineUniversity of IowaIowa CityIA52242USA; Interdisciplinary Program in Molecular and Cellular BiologyUniversity of IowaIowa CityIA52242USA
| | - Chioma M Okeoma
- Department of MicrobiologyCarver College of MedicineUniversity of IowaIowa CityIA52242USA; Interdisciplinary Program in Molecular and Cellular BiologyUniversity of IowaIowa CityIA52242USA
| |
Collapse
|
22
|
Kuji N, Mizusawa Y, Naganishi M, Hamatani T, Iwata S, Yoshimura Y. Elimination of HIV-1 from semen and application of the processed semen to assisted reproductive technology. Reprod Med Biol 2007; 6:151-156. [PMID: 29699272 DOI: 10.1111/j.1447-0578.2007.00178.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
As HIV infection is becoming a controllable chronic infection after the introduction of the highly active antiretroviral therapy (HAART), patients with this infection are now able to make plans for the future. Numerous serodiscordant (HIV-positive men and HIV-negative women) couples seek medical assistance to have a child with minimum risk to the HIV-negative female partner and the child using processed (washed) sperm. HIV-1 elimination from the semen using density gradient centrifugation and the swim-up procedure, which is a standard processing procedure, depends on both sperm motility and the physical properties of the virus-containing particles. To establish a simple method for recovering sperm from poor quality semen, we developed the tilted-tube rotation method to generate a continuous density gradient, and using this continuous density gradient we have succeeded in recovering motile sperm, even from the semen of seropositive males with severe male factors. This review aims to summarize the recent progress in the underlying principles and technical aspects of semen processing for elimination of HIV-1. (Reprod Med Biol 2007; 6: 151-156).
Collapse
Affiliation(s)
- Naoaki Kuji
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
| | - Yuri Mizusawa
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
| | - Miwa Naganishi
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
| | - Toshio Hamatani
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
| | - Sokichi Iwata
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
| | - Yasunori Yoshimura
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|